Updates are available Correction dated 2022-11-21
Click to view Correction: https://doi.org/10.1038/s41592-022-01717-7
-
Authors
Kim, Junbum http://orcid.org/0000-0001-7344-1593
Rustam, Samir
Mosquera, Juan Miguel http://orcid.org/0000-0003-4666-6476
Randell, Scott H. http://orcid.org/0000-0001-5351-2841
Shaykhiev, Renat
Rendeiro, André F. http://orcid.org/0000-0001-9362-5373
Elemento, Olivier http://orcid.org/0000-0002-8061-9617
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (T32CA203702, R01CA194547)
Leukemia and Lymphoma Society (SCOR 7021-20)
- License Information
-
More Information
Article History
Received: 15 March 2022
Accepted: 21 September 2022
First Online: 31 October 2022
Change Date: 21 November 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41592-022-01717-7
Competing interests
: O.E. is scientific advisor and equity holder in Freenome, Owkin, Volastra Therapeutics and OneThree Biotech. The remaining authors declare no competing interests.
Free to read: This content has been made available to all.
